Among patients with advanced disease, structural disease growth rate can be estimated and monitored through sequential imaging studies using RECIST criteria to document tumor size increases over time, and by measuring serum calcitonin or CEA levels at multiple time points to determine tumor marker doubling time (DT) [1]. The gene discussed is CALCA; the disease is neoplasm.